Literature DB >> 29911117

Evaluation of prodynorphin gene polymorphisms and their association with heroin addiction in a sample of the southeast Iranian population.

Mohammad Hashemi1,2, Mansour Shakiba3, Sara Sanaei2, Ghazaleh Shahkar2, Maryam Rezaei2, Azizolla Mojahed4, Gholamreza Bahari2.   

Abstract

Genetic factors are supposed to account for about 30-50% of the predisposition to cocaine and heroin addiction. This study aims at investigating the effect of rs2281285, rs2235749, rs910080 and 68bp VNTR polymorphisms of prodynorphin (PDYN) gene on heroin dependence risk in a sample of the southeast Iranian population. This case-control study was done on 216 heroin dependence subjects and 219 healthy subjects. Genomic DNA was extracted from peripheral blood cells using salting out method. Genotyping of PDYN polymorphisms were performed using polymerase chain reaction (PCR) or PCR-RFLP method. The findings showed that PDYN rs910080 T>C variant significantly increased the risk of heroin dependence (OR=7.91, 95%CI=3.36-18.61, P<0.0001, CC vs TT; OR=7.53, 95%CI=3.30-17.16, P<0.0001, CC vs TT+TC; OR=1.75, 95%CI=1.33-2.32, p<0.0001, C vs T). The rs2235749 C>T, rs2281285 A>G and 68bp VNTR variants of PDYN gene were not associated with heroin dependence. Altogether, our results provide an association between rs910080 polymorphism of PDYN gene and risk of heroin dependence in a sample of the southeast Iranian population.

Entities:  

Keywords:  Addiction; Heroin; Polymorphism; Prodynorphin; VNTR

Year:  2018        PMID: 29911117      PMCID: PMC5991531          DOI: 10.22099/mbrc.2017.27182.1294

Source DB:  PubMed          Journal:  Mol Biol Res Commun        ISSN: 2322-181X


INTRODUCTION

It has been suggested that both genetic and environmental factors contribution to individual differences in vulnerability to drug addictions [1]. Drug addiction is described as a chronic disease characterized by compulsive drug seeking, drug abuse, physical dependence and tolerance [2]. Twin studies have proposed that genetic factors account for approximately 30-60% of the overall variance in the risk of developing drug addiction [3-5]. The PDYN gene mapped on short arm of chromosome 20 (20p13) [6]. PDYN is the precursor of the dynorphin related peptides. The PDYN plays key role in some complex traits including drug abuse [7]. DYNs, which are posttranslational products of PDYN gene, bind to opiate receptors, but bind with high affinity to kappa-opioid receptor (KOR) [8, 9]. DYN inhibits the release of dopamine and is consequently supposed to play an important role in the negative feedback regulation of dopamine [10-12]. KOR and DYNs are enriched in brain circuits that control mood, motivation, and stimulus-response (habit) formation and have been involved in drug-seeking behavior [13]. PDYN gen is polymorphic and the alterations of PDYN expression may be affected by functional polymorphisms [14]. Several studies have examined the relationship between PDYN polymorphisms and opioid addiction, but the findings were inconsistent [15-20]. Some investigations statement that the variant of PDYN significantly increased the risk of opioid and cocaine addiction [15-17, 20]; though, other studies proposed that the variant decreased the risk of addiction [18, 19]. Therefore, the present study aimed to examine the possible association between rs2235749 and rs910080 variants in the 3`-untranslated regions (3`UTR), the rs2281285 variant in the second intron, and the 68-bp VNTR polymorphism in the promoter region of PDYN gene with the risk of heroin addiction in a sample of the southeast Iranian population.

MATERIALS AND METHODS

Patients: This case-control study was done in Zahedan (southeast Iran) on 216 heroin addicts (39 females and 177 males, ages 38.4±12.1) who referred to Baharan Hospital (Psychiatric hospital of Zahedan University of Medical Sciences) for methadone maintenance therapy and 219 controls (44 females and 175 males, ages 36.2±11.0) who declared that they did not suffer substance abuse. The local Ethics Committee of the Zahedan University of Medical Sciences approved the project, and written informed consent was taken from all individuals. Two milliliter of venous blood was drawn from each participant and genomic DNA was extracted by using salting out method. Genotyping: Genotyping of the rs2281285, rs2235749, rs910080 was performed by polymerase chain reaction-restriction fragments length polymorphism (PCR-RFLP). The 68bp VNTR polymorphism was genotyped by PCR method. The primer sequences for genotyping of PDYN variants, restriction enzymes and length of the fragments are summarized in Table 1. The 20 µl reaction mixture contained 1 µl of genomic DNA (~100 ng/µl), 1 µl of primers (10 µM), 10 µl of 2X Prime Taq Premix (Genet Bio, Korea) and 7 µl ddH2O. Thermocycler conditions were as follows: 95˚C for 5 min, 30 cycles of 95˚C for 30 s, annealing temperature (Table 1) for 30 s, and 72˚C for 30 s and a final extension step of 72˚C for 10 min. Ten microliter of PCR product were digested by appropriate restriction enzyme (Table 1) and the fragments were resolved on 2.5% agarose gel electrophoresis. Alleles with 3 or 4 repeats have been designated as high (H) expression alleles and those with 1 or 2 as low (L) expression alleles [27].
Table 1

The primers used for detection of PDYN polymorphisms using PCR-RFLP or PCR methods

polymorphisms Primer sequence (5`->3`) Annealing (˚C) Restriction enzyme Fragments (bp)
rs910080 A>GF: CAATGCCCAGTGCGTATGTR: CTTTGGAGACGATGCTTTAGGT65Bsp1286IT allele, 497; C allele, 300+197
rs2235749 A>GF: TGGAAACCAAGACATCAGGR: TCATTGTTCAGAAAAGCACC62NdeIC allele, 571;T allele, 365+206
rs2281285 A>GF: GCTCAGATTTTCACTGTTCCGAR: AGCCAACATTCATGGGCTGA60HPY8IA allele, 423; G allele, 240+183
68-bp VNTRF: ATCCAAGGTCTCTCCGATGGTR: CACCAGGCGGTTAGGTAGA68-Alleles containing 1, 2, 3, or 4 repeats, produced fragments of 350, 418, 486, and 554
Statistical analysis: Independent sample t-test or χ2 test was used to compare the variable between the groups according to the data. Odds ratio (OR) with 95% confidence intervals (CIs) was calculated from logistic regression analyses to find out the impact of the polymorphisms on heroin addiction. Statistical calculations were achieved using SPSS 22 software.The level of significance was set as p<0.05. The primers used for detection of PDYN polymorphisms using PCR-RFLP or PCR methods

Results

In total 216 heroin addicts (39 females and 177 males, ages 38.4±12.1) who referred to Baharan Hospital (Psychiatric hospital of Zahedan University of Medical Sciences) for methadone maintenance therapy and 219 controls (44 females and 175 males, ages 36.2±11.0) who declared that they did not suffer substance abuse were included in the study. No significant difference was found between the groups regarding age (p=0.057) and sex (p=0.627). Table 2 shows the genotypic frequencies of PDYN polymorphisms in heroin addiction and healthy subjects. The findings proposed that PDYN rs910080 variant significantly increased the risk of heroin dependence (CC vs TT: OR=7.91, 95%CI=3.36-18.61, P<0.0001). While, the results did not show any significant association between rs2235749 C>T, rs2281285 A>G and 68bp VNTR variants of PDYN gene and heroin dependence. The genotypic frequency of the rs910080 and rs2235749 polymorphisms in controls were not consistent with Hardy-Weinberg eqilibrium (P<0.05).
Table 2

Genotypic frequencies of the PDYN polymorphisms in heroin dependent persons and healthy control subjects

Polymorphisms Cases n (%) Controls n (%) OR (95% CI) p
rs910080
TT73 (33.8)94 (42.9)1.00-
TC100 (46.3)118 (53.9)1.09 (0.73-1.64)0.681
CC43 (19.9)7 (3.2)7.91 (3.36-18.61)<0.0001
rs2235749
CC68 (31.5)65 (29.7)1.00-
CT131 (60.6)145 (66.2)0.86 (0.57 -1.31)0.527
TT17 (7.9)9 (4.1)1.81 (0.75-4.34)0.203
rs2281285
AA129 (59.7)147 (67.1)1.00-
AG82 (38.0)68 (31.1)1.37 (0.92-4.05)0.129
GG5 (2.3)4 (1.8)1.42 (0.37-5.42)0.739
68bp VNTR
3/379 (36.6)85 (38.3)1.00-
2/226 (12.0)27 (12.3)1.04 (0.56-1.93)0.911
2/395 (43.5)95 (42.9)1.08 (0.71-1.64)0.750
3/48 (3.7)4 (1.8)2.15 (0.62-7.43)0.246
2/48 (3.7)8 (3.7)1.07 (0.38-3.01)0.889
Genotypic frequencies of the PDYN polymorphisms in heroin dependent persons and healthy control subjects

DISCUSSION

Alterations in the PDYN gene expression might be influenced by genetic polymorphisms and epigenetic mechanisms. Consequently, genetic variations or epigenetic changes of the PDYN may be a risk factor drug abuse susceptibility [21, 22]. Some studies evaluated the impact of PDYN polymorphisms on heroin dependence but, the available findings remained inconsistent [15-19]. In the present study, we inspected the possible association between PDYN rs910080, rs2281285, rs2235749, and 68bp VNTR polymorphisms and heroin dependence in a sample of southeast Iranian population. The findings suggest that PDYN rs910080 T>C variant significantly increased the risk of heroin dependence. No significant association was found between rs2281285, rs2235749, and 68bp VNTR polymorphisms and heroin dependence. Growing evidence propose that dynorphin/kappa-opioid receptor system plays a significant role in alcohol and drug dependence [21, 23-25]. Saify et al [20] investigated the impact of VNTR polymorphism on heroin addiction in Shiraz, southern Iran. In contrast to our findings, they found that HL genotype and L allele significantly increased the risk of heroin addiction. Stratification by sex revealed that VNTR variant was associated with the risk of heroin addiction only in male [20]. In another study, Saify et al [26] have found no significant association between the VNTR polymorphism in the promoter region of the PDYN gene and the risk of methamphetamine dependence. Zimprich et al [27] have found no significant association between 68-bp VNTR polymorphism located in the PDYN gene promoter region and heroin addiction. One to four repeats of a 68-bp element comprising one binding site per repeat for the transcription factor AP-1 (c-Fos/c-Jun). It has been shown that alleles 3 or 4 repeats are associated with higher expression of dynorphin peptides and higher degrees of dopamine inhibition than that of alleles with 1 or 2 repeats [27]. It has been proposed that the long alleles (three or four repeats) of PDYN VNTR may be a risk factor for developing cocaine/alcohol codependence in the African American population [28, 29]. The 68-bp VNTR polymorphism of PDYN is a functional variant and influence gene expression [27]. Individuals carrying 3 or 4 copies of VNTR PDYN promoter exhibit higher PDYN expression than those with only 1 or 2 copies [18, 27]. Following studies revealed that the impact of 68-bp VNTR polymorphism on expression of PDYN is cell type dependent [30]. D'Addario et al [31] have shown that PDYN rs2235751 variant was associated with alcoholism and the presence of the minor allele G was associated with reduced PDYN promoter DNA methylation in females and younger subjects. Recently, Egervari et al [14] reported that a functional variant in the 3`-untranslated region (3`UTR) of PDYN, rs2235749, impairs the binding of miR-365 as well as PDYN expression. This finding may be a novel mechanism involving miR-365-PDYN interaction relevant to susceptibility to addiction. There are some limitations in the current study, one of which is the relative small sample sizes Second we did not perform stratification by sex due to small samples of females in the groups. Third, we evaluated 4 variants of the PDYN gene. Other genetic variants of these genes should also be evaluated. There is no clear explanation for departure from HWE regarding rs910080 and rs2235749 variants. It may be due to genetic drift. In summary, our findings support an association between PDYN rs910080 variant and risk of heroin addiction in a sample of Iranian population. Further investigation with larger sample sizes and diverse ethnicities are required to authenticate our findings.
  31 in total

Review 1.  The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse.

Authors:  Sunmee Wee; George F Koob
Journal:  Psychopharmacology (Berl)       Date:  2010-03-30       Impact factor: 4.530

Review 2.  Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior.

Authors:  H Steiner; C R Gerfen
Journal:  Exp Brain Res       Date:  1998-11       Impact factor: 1.972

3.  Genetic and environmental influences on drug use and abuse/dependence in male and female twins.

Authors:  M B van den Bree; E O Johnson; M C Neale; R W Pickens
Journal:  Drug Alcohol Depend       Date:  1998-11-01       Impact factor: 4.492

Review 4.  Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment.

Authors:  Vadim Yuferov; Orna Levran; Dmitri Proudnikov; David A Nielsen; Mary Jeanne Kreek
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

Review 5.  κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction.

Authors:  Eduardo R Butelman; Vadim Yuferov; Mary Jeanne Kreek
Journal:  Trends Neurosci       Date:  2012-06-16       Impact factor: 13.837

6.  Cell-specific effects of variants of the 68-base pair tandem repeat on prodynorphin gene promoter activity.

Authors:  Morgane Rouault; David A Nielsen; Ann Ho; Mary Jeanne Kreek; Vadim Yuferov
Journal:  Addict Biol       Date:  2010-08-23       Impact factor: 4.280

7.  An association of prodynorphin polymorphisms and opioid dependence in females in a Chinese population.

Authors:  Toni-Kim Clarke; Kristina Krause; Tao Li; Gunter Schumann
Journal:  Addict Biol       Date:  2009-03-05       Impact factor: 4.280

8.  Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex.

Authors:  Elyssa B Margolis; Hagar Lock; Vladimir I Chefer; Toni S Shippenberg; Gregory O Hjelmstad; Howard L Fields
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205

9.  Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities.

Authors:  M T Tsuang; M J Lyons; J M Meyer; T Doyle; S A Eisen; J Goldberg; W True; N Lin; R Toomey; L Eaves
Journal:  Arch Gen Psychiatry       Date:  1998-11

10.  A Functional 3'UTR Polymorphism (rs2235749) of Prodynorphin Alters microRNA-365 Binding in Ventral Striatonigral Neurons to Influence Novelty Seeking and Positive Reward Traits.

Authors:  Gabor Egervari; Didier Jutras-Aswad; Joseph Landry; Michael L Miller; Sarah Ann Anderson; Michael Michaelides; Michelle M Jacobs; Cyril Peter; Georgia Yiannoulos; Xun Liu; Yasmin L Hurd
Journal:  Neuropsychopharmacology       Date:  2016-04-14       Impact factor: 7.853

View more
  4 in total

1.  Association of Alcohol Use Disorder Risk With ADH1B, DRD2, FAAH, SLC39A8, GCKR, and PDYN Genetic Polymorphisms.

Authors:  Evangelia Legaki; Domna Tsaklakidou; Alex Hatzimanolis; Eirini Segredou; Markos Petalotis; Giannoula Moularogiorgou; Varvara Mouchtouri; Lefteris Lykouras; Nikos C Stefanis; Maria Gazouli
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

2.  Association between prodynorphin gene polymorphisms and opioid dependence susceptibility: a meta-analysis.

Authors:  Chang-Wang Wang; Min Ma; Wei-Guang Lu; Ru-Qin Luo
Journal:  BMC Psychiatry       Date:  2019-09-11       Impact factor: 3.630

3.  Lack of Association between rs4680 Polymorphism in Catechol-O-Methyltransferase Gene and Alcohol Use Disorder: A Meta-Analysis.

Authors:  Xin-Rong Jin; Zhi-Qiang Zhao
Journal:  Dis Markers       Date:  2020-11-17       Impact factor: 3.434

Review 4.  Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders.

Authors:  Jamie A Burns; Danielle S Kroll; Dana E Feldman; Christopher Kure Liu; Peter Manza; Corinde E Wiers; Nora D Volkow; Gene-Jack Wang
Journal:  Front Psychiatry       Date:  2019-09-18       Impact factor: 4.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.